Rosetta Genomics

Rosetta Genomics Ltd. is a global genomic diagnostics company based in Rehovot, Israel, specializing in microRNA-based diagnostic tests. The company offers several products, including RosettaGX Cancer Origin for identifying the primary site of metastatic cancer, mi-KIDNEY for kidney tumor classification, RosettaGX Reveal for diagnosing indeterminate thyroid fine-needle aspirate samples, and mi-LUNG for lung cancer diagnostics. Additionally, Rosetta Genomics provides UroVysion, a urine-based assay for bladder carcinoma, as well as FISH-based prognostic tests for prostate cancer and predictive tests for late-stage lung cancer. The company's diagnostic solutions are designed to assist oncologists, urologists, endocrinologists, cytopathologists, and other medical specialists in patient care. Rosetta Genomics is involved in research collaborations, including a partnership with Meir Medical Center to develop a microRNA classifier for non-small cell lung cancer patients. Founded in 2000, the company is committed to advancing personalized medicine through its innovative diagnostic offerings.